GlaxoSmithKline submits regulatory application for UMEC/VI

A.B. | ShareCast | 18 Dec, 2012 12:05 - Updated: 12:58 | | |

needle

Pharmaceutical companies GlaxoSmithKline (GSK) and Theravance have submitted a regulatory application in the US for UMEC/VI medicine, used to treat chronic obstructive pulmonary disease (COPD).

UMEC/VI is an investigational once-daily LAMA/LABA combination medicine. It includes properties, umeclidinium bromide --- a long-acting muscarinic antagonist (LAMA)--- and vilanterol, a long-acting beta2 agonist which is administered using the Ellipta inhaler.

The application proposes the proprietary name Anora Ellipta and has been submitted to the US Food and Drug Administration for the long-term once-daily maintenance bronchodilator treatment of airflow obstruction in patients with COPD, including chronic bronchitis and emphysema.

Applications for UMEC/VI are also planned in the European Union and in other countries next year.

FSTE 100 company GSK is a leading research-based pharmaceutical and healthcare company.

Theravance is a biopharmaceutical company which collaborates with a number of pharmaceutical organisations.

RD

More news

24 Oct US close: Markets end the week largely unchanged, as Ford and Amazon fall

US stocks were largely unchanged on Friday, as investors looked to be worried by reports of a first Ebola case in New York, while the focus remained on companies results.

24 Oct Fitch affirms Spain and Italy at BBB+, both with stable outlook

24 Oct Three people hospitalised after shooting at Seattle high school

24 Oct Apple iTunes sales plummet

iTunes sales have fallen 13% to 14% world-wide since January 2014, underlining the precarious nature of the music industry’s recovery.

24 Oct GoPro shares slumps as Oppenheimer initiates covearege of the stock at sell

24 Oct S&P upgrades Cyprus on strong budget performance

Rating agency Standard & Poor's has upgraded European economic struggler Cyprus, citing a strong budgetary performance.

24 Oct Market overview: S&P downgrades Tesco

1630:Close The Footsie ended the session lower ahead of this weekend’s ECB stress tests and after an initial feint lower in US stocks. Significantly, on Friday ECB president Mario Draghi sounded a clarion call to action, warning leaders from the European Union that a "joint effort" is required to avoid a "relapse into recession." Tullow continued to reel under the pressure of low oil prices but Pearson did worst on the top flight index after announcing that its CFO was leaving. Intercontinental Hotels Group was also to be seen lower following reports overnight of an Ebola infection in NY. Heading the other way was Shire. The firm updated investors on its third quarter results. Tesco managed to hold on to the nearest level of technical support at 168p – at least for now. FTSE 100 down 30 to 6,388.7.

24 Oct US open: Markets fluctuate amid renewed Ebola fears, while Ford and Amazon drop

US stocks were largely unchanged on Friday, as investors looked to be worried by reports of the first Ebola case in New York, while the focus remained on company results.

24 Oct City's mayor says NYC fully prepared to deal with Ebola

Bill De Blasio, New York City's mayor, said the city was "fully prepared" to deal with the Ebola virus.

24 Oct Europe close: Stocks end on a mixed note

European equities finished the Friday session on a mixed note as investors kept their cards close to their chests ahead of the European Central Bank’s (ECB) ‘stress tests’ which were due out this weekend.

Advertising

HIGHLIGHTS

New York
Ebola latest: The NYPD has been photographed throwing hazmat suits and gloves into public bins

Welcome to our rolling coverage of the Ebola crisis. Refresh for updates on the outbreak as they happen.

VIDEOS

EUR/USD: continues its clearly bearish trend
REGISTER NOW!